Taken together, we confirmed that Trastuzumab- and Cetuximab-mediated ADCC was impaired in patients with ESCC in comparison with those in healthy donors, although HER2-expressing or EGFR-expressing ESCC was killed by Trastuzumab- and Cetuximab-mediated ADCC, respectively. This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.